Læknablaðið - 15.09.1983, Blaðsíða 65

LÆKNABLADID
233
regard to radiotherapy. Am J Roentgenol Rad
Ther Nucl Med 1971; 111:417.
19) Long RTL, Johnson RE, Sala JM. Variations in
survival among patients with carcinoma of the
ovary. Analyses of 253 cases according to
histologic type, anatomical stage and method of
treatment. Cancer 1967; 20: 1195.
20) Edmonson JH, Fleming TR, Decker DG et al.
Different chemotherapeutic sensitivities and
lost factors affecting prognosis in advanced
ovarian carcinoma versus minimal residual dis-
ease. Cancer Treat Rep 1979; 63: 241.
21) Munnell EW. The changing prognosis and
treatment in cancer of the ovary. A report of
235 patients with primary ovarian carcinoma
1952-1961. Am J Obstet Gynecol 1968; 100: 790-
805.
22) Pomerance W, Moltz A, Hall EJ. Factors
influencing survival in ovarian carcinoma. Am J
Obstet Gynecol 1966; 96: 418-42.
23) Kolstad P. Prognostic indicators and staging.
Advances in the biosciences. Ovarian Cancer.
Oxford, Pergamon Press 1980; 26: 67-75.
24) Kalbfleisch ID, Prentice RL. The statistical
analysis of failure. New York, pp 70-117, Wiley
and Sons, 1980.
25) Griffiths CT. Surgical resection of tumour bulk
in the primary treatment of ovarian carcinoma.
National Cancer Institute Monograph 1975; 42:
101-4.
26) Sigurdsson K. Malignant epithelial ovarian tu-
mours. A study of prognostic factors and the
effects of combined treatments. Thesis. The
University of Lund, Sweden, 1982.
27) Sigurdsson K, Alm P, Gullberg B. Prognostic
Factors In Malignant Epithelial Ovarian Tu-
mours. Gynecologic Oncology. 1983; 15: 370-80.
28) Peto R, Pike MC, Armitage P et al. Design and
analysis of randomized clinical trials requiring
prolonged observation of each patient. II ana-
lysis and examples. Br J Cancer 1977; 35: 3-7.
29) Lee E, Desu M. A computer Program for
comparing K-Samples with Right-Censored
Data. Computer Programs in Biomedicine 1972;
2:315-21.
30) Munell EW. Is conservative therapy ever justifi-
ed in stage I (Ia) cancer of the ovary. Am J-
Obstet Gynecol 1969; 103: 641.
31) Williams TJ, Dockerth MB. Status of the contra-
lateral ovary in encapsulated low grade malig-
nant tumours of the ovary. Surgery, Gynecolo-
gy & Obstetrics 1976; 143: 763.
32) Sigurdsson K, Johnsson JE, Tropé Claes. Carci-
noma of the ovary, stages I and II. A prospecti-
ve randomized study of the effects of postoper-
ative chemotherapy and radiotherapy. Ann
Chir et Gynecol 1982; 71: 321.
33) Smith WG. Surgical treatment of epithelial
ovarian carcinoma. Clin Obstet Gynecol 1979;
22:939.
34) Kottmeier HL. Cancer of the ovary and its
treatment in Sweden. In: Progress in Gynecolo-
gy (eds Meigs JV, Sturgis SH) 4 ed. New York,
p 426 Grune & Stratton 1963.
35) Sigurdsson K, Johnsson JE, Tropé C. Carcinoma
of the ovary in stage III. Effects of postoperati-
ve chemotherapy, radiation therapy and repeat
laparotomy. Acta Radiologica Oncology 1982;
21: 181.
36) Sigurdsson K. Advanced stage III ovarian
carcinoma. Prospective randomized trials com-
paring radiotherapy and chemotherapy. To be
published.
37) Fuks Z: Patterns of spread of ovarian carcino-
ma: Relation to therapeutic strategies. Advan-
ces in the biosciences. Ovarian Cancer. Oxford,
Pergamon Press 1980; 26: 39-51.
38) Knapp RC, Friedman EA. Aortic lymphnode
metastases in early ovarian cancer. Am J Obstet
Gynecol 1974; 119: 1013.
39) Dembo AJ, Bush RS, Beale FA et al. Ovarian
carcinoma: Improved survival following abdo-
minopelvic irradiation in patients with comple-
ted pelvic operation. Am J Obstet Gynecol
1979; 134: 793.
40) Hall EJ. Radiobiology for the radiologists, 2 ed
New York. Harper & Row 1978.
41) Wiltshaw E. Cisplatin in adenocarcinoma of the
ovary. A critical review. Advances in the
biosciences. Ovarian Cancer. Oxford, Pergamon
Press 1980; 26: 179-185.
42) Priestman TJ. Cancer chemotherapy — an
introduction 2 ed. Farmitalia Carlo Erba Ltd.
Pharmaprint Limited 1980.
43) Young RC, Chabner BA, Hubbard SP et al.
Advanced ovarian adenocarcinoma: A prospec-
tive clinical trial of Melphalan (L- PAM) versus
combination chemotherapy. N Engl J Med
1978:299: 1261.
44) Holland JF, Bruckner HW, Cohen CJ et al.
Cisplatin therapy of ovarian cancer. Therapeu-
tic progress in ovarian cancer, testicular cancer
and the sarcomas. Leiden University Press,
Boerhaave Series 1980; 16: 41.
45) Lewis B, Young R. Adjuvant and first line
chemotherapy for ovarian cancer. Advances in
the biosciences. Ovarian Cancer. Oxford, Perga-
mon Press 1980; 26: 165-77.
46) Lewis CG jr, Blessing J. Ovarian cancer. Use of
multiple modality programs involving surgery,
radiation therapy and chemotherapy. Cancer
1977:40:588.
47) Smith JP, Rutledge F, Wharton TJ. Chemother-
apy of ovarian cancer. New approaches to
treatment. Cancer 1972; 30: 1565.
48) Hreshchyshyn MM, Park RC, Blessing JA et al.
The role of adjuvant therapy in stage 1 ovarian
cancer. Am J Obstet Gynecol 1980; 138: 139.
49) Smith JP, Rutledge FN, Delclos L. Results of